Stockscreener 앱 받기
6.10
3.71%
-0.235
전일 마감가:
$6.335
열려 있는:
$6.34
하루 거래량:
77,895
Relative Volume:
28.18
시가총액:
$24.06M
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
+0.00%
1개월 성능:
+0.00%
6개월 성능:
+0.00%
1년 성능:
+0.00%
1일 변동 폭
$6.07
$6.34
1주일 범위
$6.07
$6.625
52주 변동 폭
$6.07
$6.625
Leonabio Inc Stock (LONA) Company Profile
명칭
Leonabio Inc
전화
(425) 620-8501
주소
18706 NORTH CREEK PARKWAY, SUITE 104, BOTHELL
LONA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
LONA
Leonabio Inc
|
6.10 | 24.98M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.36 | 111.36B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
733.04 | 77.98B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
800.01 | 50.33B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
359.27 | 47.46B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
338.19 | 37.43B | 4.98B | 69.59M | 525.67M | 0.5197 |
Leonabio Inc Stock (LONA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-09-19 | 다운그레이드 | Mizuho | Outperform → Neutral |
| 2024-09-04 | 다운그레이드 | BTIG Research | Buy → Neutral |
| 2024-09-04 | 다운그레이드 | JMP Securities | Mkt Outperform → Mkt Perform |
| 2024-09-04 | 다운그레이드 | Rodman & Renshaw | Buy → Neutral |
| 2024-08-19 | 개시 | Rodman & Renshaw | Buy |
| 2022-10-17 | 업그레이드 | JMP Securities | Mkt Perform → Mkt Outperform |
| 2022-07-07 | 개시 | Mizuho | Buy |
| 2022-06-23 | 다운그레이드 | JMP Securities | Mkt Outperform → Mkt Perform |
| 2022-06-23 | 다운그레이드 | Jefferies | Buy → Hold |
| 2022-06-23 | 다운그레이드 | Stifel | Buy → Hold |
| 2022-05-10 | 개시 | BTIG Research | Buy |
| 2022-04-21 | 개시 | Berenberg | Buy |
| 2021-12-15 | 개시 | Goldman | Neutral |
| 2020-10-13 | 개시 | Goldman | Buy |
| 2020-10-13 | 개시 | JMP Securities | Mkt Outperform |
| 2020-10-13 | 개시 | Jefferies | Buy |
| 2020-10-13 | 개시 | Stifel | Buy |
모두보기
Leonabio Inc 주식(LONA)의 최신 뉴스
Athira Pharma Announces Name Change to LeonaBio, Inc. with New Ticker "LONA" - Investing News Network
Athira Pharma (ATHA) Options to Be Delisted on January 12th - GuruFocus
Athira Pharma Rebrands as LeonaBio, Refocusing on Oncology - TipRanks
Athira Pharma announces name change to LeonaBio - TipRanks
Athira Pharma roars into the new year with rebrand to LeonaBio - Fierce Pharma
Athira Pharma changes name, ticker symbol - MSN
Athira Pharma rebrands as LeonaBio amid strategic pivot to cancer therapy - Investing.com Nigeria
Athira Pharma rebrands as LeonaBio amid strategic pivot to cancer therapy By Investing.com - Investing.com South Africa
Athira Pharma Announces Name Change to LeonaBio, Inc. with New Ticker “LONA” - Yahoo Finance
New breast cancer drug moves into late testing with $236M funding deal - Stock Titan
Athira Pharma Announces Reverse Stock Split - GlobeNewswire
Athira Pharma to Focus on Advancement of ATH-1105 for the Treatment of Neurodegenerative Diseases - marketscreener.com
Athira Pharma Presents Preclinical Data Demonstrating New Insights into the Mechanism by Which Fosgonimeton Protects Neurons from Alzheimer's Disease-Related Pathology - marketscreener.com
Athira Pharma Announces Upcoming Presentation at Motor Neurone Disease Association’s 34ᵗʰ International Symposium on ALS/MND - marketscreener.com
Athira Pharma, Inc. Plans to Further Extend the Current OLEX for the Phase 2/3 LIFT-AD and Phase 2 ACT-AD Trials - marketscreener.com
Athira Pharma Provides 2023 Pipeline Outlook - marketscreener.com
Athira Pharma Reports First Quarter 2022 Financial Results and Provides Pipeline and Business Updates - marketscreener.com
Alzheimer’s Disease Stock Cortexyme Craters on Trial Failure - Bloomberg
ATHAAthira Pharma, Inc. Latest Stock News & Market Updates - Stock Titan
Leonabio Inc (LONA) 재무 분석
Leonabio Inc (LONA)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
Leonabio Inc 주식 (LONA) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| San Martin Javier | CHIEF MEDICAL OFFICER |
Jan 02 '26 |
Sale |
6.88 |
1,644 |
11,311 |
10,189 |
| Litton Mark James | President and CEO |
Dec 31 '25 |
Option Exercise |
0.00 |
10,834 |
0 |
43,414 |
| Litton Mark James | President and CEO |
Jan 02 '26 |
Sale |
6.88 |
2,586 |
17,792 |
40,828 |
| Renninger Robert | Chief Financial Officer |
Dec 31 '25 |
Option Exercise |
0.00 |
1,236 |
0 |
13,154 |
| Renninger Robert | Chief Financial Officer |
Jan 02 '26 |
Sale |
6.88 |
297 |
2,043 |
12,857 |
| CHURCH KEVIN | CHIEF SCIENTIFIC OFFICER |
Dec 31 '25 |
Option Exercise |
0.00 |
3,667 |
0 |
21,557 |
| CHURCH KEVIN | CHIEF SCIENTIFIC OFFICER |
Jan 02 '26 |
Sale |
6.88 |
876 |
6,027 |
20,681 |
| Worthington Mark | General Counsel and CCO |
Dec 31 '25 |
Option Exercise |
0.00 |
3,667 |
0 |
14,854 |
| Worthington Mark | General Counsel and CCO |
Jan 02 '26 |
Sale |
6.88 |
876 |
6,027 |
13,978 |
| CHURCH KEVIN | CHIEF SCIENTIFIC OFFICER |
Jun 30 '25 |
Option Exercise |
0.00 |
36,666 |
0 |
177,427 |
4.73%
0.92%
자본화:
|
볼륨(24시간):